Travere Therapeutics (TVTX) Gross Profit (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Gross Profit came in at $125.2 million in Q1 2026, up 62.55% YoY from $77.1 million in Q1 2025, and up 135.35% on a QoQ basis from -$354.3 million in Q4 2025.
Travere Therapeutics (TVTX) Gross Profit (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Gross Profit data on file, last reported at $125.2 million in Q1 2026.
- Quarterly Gross Profit rose 62.55% year-over-year to $125.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.7 million (down 129.59% YoY) and the FY2025 annual result came in at -$1.0 million, down 100.46% from the prior year.
- Gross Profit improved to $125.2 million in Q1 2026, from -$354.3 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $125.2 million in Q1 2026 to a low of -$354.3 million in Q4 2025.
- A 5-year average of $27.2 million and a median of $38.4 million in 2025 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2022 — Gross Profit jumped 118.11% — and 2025, when it tumbled 590.48%.
- Tracing TVTX's Gross Profit over 5 years: stood at $28.5 million in 2022, then soared by 42.23% to $40.5 million in 2023, then jumped by 78.38% to $72.2 million in 2024, then plunged by 590.48% to -$354.3 million in 2025, then surged by 135.35% to $125.2 million in 2026.
- The last three Gross Profit figures came in at $125.2 million (Q1 2026), -$354.3 million (Q4 2025), and $38.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.52 Mn |
| Jun 30, 2026 | 162.52 Mn |
| Mar 31, 2026 | 125.25 Mn |
| Mar 31, 2026 | 125.25 Mn |
| Dec 31, 2025 | -354.29 Mn |
| Dec 31, 2025 | -354.29 Mn |
| Sep 30, 2025 | 38.42 Mn |
| Sep 30, 2025 | 38.42 Mn |
| Jun 30, 2025 | 112.93 Mn |
| Jun 30, 2025 | 112.93 Mn |
| Mar 31, 2025 | 77.05 Mn |
| Mar 31, 2025 | 77.05 Mn |
| Dec 31, 2024 | 72.23 Mn |
| Dec 31, 2024 | 72.23 Mn |
| Sep 30, 2024 | 61.27 Mn |
| Sep 30, 2024 | 61.27 Mn |
| Jun 30, 2024 | 52.06 Mn |
| Jun 30, 2024 | 52.06 Mn |
| Mar 31, 2024 | 39.87 Mn |
| Mar 31, 2024 | 39.87 Mn |